Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with upcoming UK export approvals and a planned European GMP facility.
- Q2 revenue of $6.1 million, up 77% from Q1 and 310% year-on-year
- Positive operating cash flow of $1.5 million for the quarter
- Manufacturing capacity expansion to triple pastilles output by February 2025
- Regulatory approvals imminent for UK exports of Dr Watson products
- Planning underway for GMP manufacturing facility in Europe
Robust Revenue Growth and Cash Flow Momentum
Bioxyne Limited (ASX:BXN) has delivered an impressive second quarter for the 2025 financial year, reporting $6.1 million in revenue, a 77% increase over the previous quarter and a staggering 310% rise compared to Q2 FY2024. This surge underscores the company’s accelerating market traction, particularly through its subsidiary Breathe Life Sciences (BLS) Australia, which continues to lead the group’s growth trajectory.
Alongside top-line expansion, Bioxyne achieved positive operating cash flow of $1.5 million for the quarter, driven by cash receipts of $7.4 million. This marks the second consecutive quarter of positive cash flow, a significant milestone for a company scaling its manufacturing and distribution footprint.
Capacity Expansion to Meet Growing Demand
In response to rising demand, Bioxyne invested approximately $1.3 million in the first half of FY2025 to enhance its manufacturing infrastructure. The upgraded facilities, including new plant equipment and security vaults, are set to be commissioned by mid-February 2025. This expansion will triple the production capacity for pastilles and enable scaling of other product lines, positioning the company to capitalize on its expanding customer base and product portfolio.
Regulatory Progress and International Ambitions
Bioxyne is on the cusp of securing regulatory approvals to export its Dr Watson branded pharmaceutical products to the UK, a move that could unlock significant new revenue streams. Concurrently, the company is advancing plans for a Good Manufacturing Practice (GMP) facility in Europe, aimed at meeting local demand and strengthening its foothold in key international markets.
These strategic initiatives align with Bioxyne’s broader vision to grow its manufacturing customer base, expand market share for Dr Watson products in Australia, and introduce its proprietary PCC probiotic products globally.
Operational Discipline and Outlook
Despite rapid growth, Bioxyne maintains rigorous cost controls and aims to sustain cash flow positivity and profitability throughout FY2025. The company ended the quarter with $2.7 million in cash on hand, providing a solid financial foundation for ongoing expansion.
CEO Sam Watson praised the team’s achievements, highlighting the balance between scaling operations and upholding high-quality standards, particularly in pharmaceutical-grade manufacturing. The upcoming half-year results, due by 28 February 2025, will provide further clarity on the company’s financial trajectory.
Bottom Line?
Bioxyne’s strong Q2 performance and strategic international moves set the stage for a transformative year ahead.
Questions in the middle?
- Will Bioxyne secure UK export approvals on schedule, and how will this impact revenue?
- What is the timeline and expected capacity for the proposed European GMP manufacturing facility?
- How will Bioxyne manage cost controls while scaling rapidly to sustain profitability?